Suppr超能文献

非酒精性脂肪性肝病患者肝细胞癌的代谢危险因素:一项前瞻性研究

Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study.

作者信息

Antwi Samuel O, Craver Emily C, Nartey Yvonne A, Sartorius Kurt, Patel Tushar

机构信息

Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.

Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.

出版信息

Cancers (Basel). 2022 Dec 17;14(24):6234. doi: 10.3390/cancers14246234.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a fast-growing public health problem and predisposes to hepatocellular carcinoma (HCC) in a significant proportion of patients. Metabolic alterations might underlie the progression of NAFLD to HCC, but the magnitudes of risk and population-attributable risk fractions (PAFs) for various metabolic conditions that are associated with HCC risk in patients with NAFLD are unknown. We investigated the associations between metabolic conditions and HCC development in individuals with a prior history of NAFLD. The study included 11,245 participants in the SEER-Medicare database, comprising 1310 NAFLD-related HCC cases and 9835 NAFLD controls. We excluded individuals with competing liver diseases (e.g., alcoholic liver disease and chronic viral hepatitis). Baseline pre-existing diabetes mellitus, dyslipidemia, obesity, hypertension, hypothyroidism, and metabolic syndrome were assessed. Multivariable-adjusted logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). PAFs were also calculated for each metabolic condition. The results show that diabetes (OR = 2.39, 95% CI: 2.04-2.79), metabolic syndrome (OR = 1.73, 95% CI: 1.49-2.01), and obesity (OR = 1.62, 95% CI: 1.43-1.85) were associated with a higher HCC risk in individuals with NAFLD. The highest PAF for HCC was observed for pre-existing diabetes (42.1%, 95% CI: 35.7-48.5), followed by metabolic syndrome (28.8%, 95% CI: 21.7-35.9) and obesity (13.2%, 95% CI: 9.6-16.8). The major predisposing factors for HCC in individuals with NAFLD are diabetes mellitus, metabolic syndrome, and obesity, and their control would be critically important in mitigating the rising incidence of NAFLD-related HCC.

摘要

非酒精性脂肪性肝病(NAFLD)是一个迅速增长的公共卫生问题,在相当一部分患者中易引发肝细胞癌(HCC)。代谢改变可能是NAFLD进展为HCC的基础,但与NAFLD患者HCC风险相关的各种代谢状况的风险程度和人群归因风险分数(PAF)尚不清楚。我们调查了有NAFLD病史个体的代谢状况与HCC发生之间的关联。该研究纳入了SEER - 医疗保险数据库中的11245名参与者,包括1310例与NAFLD相关的HCC病例和9835例NAFLD对照。我们排除了患有其他竞争性肝病(如酒精性肝病和慢性病毒性肝炎)的个体。评估了基线时已存在的糖尿病、血脂异常、肥胖、高血压、甲状腺功能减退和代谢综合征。采用多变量调整逻辑回归计算比值比(OR)和95%置信区间(CI)。还计算了每种代谢状况的PAF。结果显示,糖尿病(OR = 2.39,95% CI:2.04 - 2.79)、代谢综合征(OR = 1.73,95% CI:1.49 - 2.01)和肥胖(OR = 1.62,95% CI:1.43 - 1.85)与NAFLD个体的HCC风险较高相关。HCC的最高PAF见于已存在的糖尿病(42.1%,95% CI:35.7 - 48.5),其次是代谢综合征(28.8%,95% CI:21.7 - 35.9)和肥胖(13.2%,95% CI:9.6 - 16.8)。NAFLD个体发生HCC的主要危险因素是糖尿病、代谢综合征和肥胖,对它们的控制对于减轻NAFLD相关HCC发病率的上升至关重要。

相似文献

2
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103.
4
NAFLD and MAFLD as emerging causes of HCC: A populational study.
JHEP Rep. 2021 Jan 19;3(2):100231. doi: 10.1016/j.jhepr.2021.100231. eCollection 2021 Apr.
5
Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease.
Hepatology. 2020 Mar;71(3):808-819. doi: 10.1002/hep.31014. Epub 2020 Feb 26.
7
Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States.
Am J Gastroenterol. 2013 Aug;108(8):1314-21. doi: 10.1038/ajg.2013.160. Epub 2013 Jun 11.
8
Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India.
Indian J Gastroenterol. 2017 Sep;36(5):373-379. doi: 10.1007/s12664-017-0785-x. Epub 2017 Oct 4.

引用本文的文献

1
Global burden and international disparities in NASH-associated liver Cancer: mortality trends (1990-2021) and future projections to 2045.
Front Public Health. 2025 Feb 14;13:1527328. doi: 10.3389/fpubh.2025.1527328. eCollection 2025.
2
Risk and Prognosis of Hepatocellular Carcinoma in Mexican Americans with Type 2 Diabetes Mellitus.
J Hepatocell Carcinoma. 2025 Jan 21;12:93-106. doi: 10.2147/JHC.S477141. eCollection 2025.
6
Analysis of competing risks of cardiovascular death in patients with hepatocellular carcinoma: A population-based study.
Medicine (Baltimore). 2023 Dec 22;102(51):e36705. doi: 10.1097/MD.0000000000036705.
7
Gastrointestinal Tract Cancers, an Increasing Burden of the Modern Era: Epidemiology and Prevention.
Cancers (Basel). 2023 Sep 19;15(18):4634. doi: 10.3390/cancers15184634.
10
Population-attributable risk of modifiable lifestyle factors to hepatocellular carcinoma: The multi-ethnic cohort.
Aliment Pharmacol Ther. 2023 Jul;58(1):89-98. doi: 10.1111/apt.17523. Epub 2023 Apr 13.

本文引用的文献

1
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).
Signal Transduct Target Ther. 2022 Aug 13;7(1):287. doi: 10.1038/s41392-022-01119-3.
2
The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products.
Front Pharmacol. 2022 Jul 7;13:944088. doi: 10.3389/fphar.2022.944088. eCollection 2022.
3
Cancer statistics, 2022.
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
4
Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk.
Dig Liver Dis. 2022 Jul;54(7):964-972. doi: 10.1016/j.dld.2021.12.002. Epub 2021 Dec 23.
6
Advancing the global public health agenda for NAFLD: a consensus statement.
Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):60-78. doi: 10.1038/s41575-021-00523-4. Epub 2021 Oct 27.
7
Epidemiology and risk-stratification of NAFLD-associated HCC.
J Hepatol. 2021 Dec;75(6):1476-1484. doi: 10.1016/j.jhep.2021.08.012. Epub 2021 Aug 25.
8
NAFLD-Associated HCC: Progress and Opportunities.
J Hepatocell Carcinoma. 2021 Apr 8;8:223-239. doi: 10.2147/JHC.S272213. eCollection 2021.
9
Molecular Mechanisms Linking Nonalcoholic Steatohepatitis to Cancer.
Clin Liver Dis (Hoboken). 2021 Feb 1;17(1):6-10. doi: 10.1002/cld.1006. eCollection 2021 Jan.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验